OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update
(WorldNews France)

OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update 17 Sep 2020 18:00 CEST Company Name OSE IMMUNO ISN FR0012127173 Market Euronext Symbol OSE Positive results for Step-1 of Phase 3 clinical trial of Tedopi® in non-small cell lung cancer Positive preclinical and in human ex vivo results with CoVepiT vaccine against COVID-19; clinical entry expected by the end of 2020 or early 2021 Two Phase 2 clinical trials with OSE-127 planned to start in Q4 2020 in ulcerative colitis and in the Sjögren syndrome Strong progress on BiCKI®, bi-specific platform, and CLEC-1 antagonist preclinical programs in immuno-oncology €7 million non-dilutive loan agreement guaranteed by the...